Rutaba Tajammal

Rutaba Tajammal practices at UPMC Passavant-McCandless in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Rutaba Tajammal's NPI, 1144880311, was assigned on June 19, 2019. Rutaba Tajammal holds Pennsylvania license MD482255.

Rutaba Tajammal's primary practice is UPMC Passavant-McCandless, at 9100 Babcock Boulevard, Pittsburgh, PA 15237 in Allegheny County. The practice phone is (412) 367-6700.

Rutaba Tajammal's primary practice is UPMC Passavant-McCandless in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Rutaba Tajammal is also affiliated with UPMC Magee-Womens Hospital. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Rutaba Tajammal to 3 more group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rutaba Tajammal practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Rutaba Tajammal's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Rutaba Tajammal's licenses on file in 2 states: Pennsylvania and Massachusetts.

CMS data shows 211 Medicare services from Rutaba Tajammal across 7 procedure codes in 2024, for 96 Medicare patients. Medicare paid $16,268 for them. Every service was in an office.

CMS counts 96 Medicare patients who saw Rutaba Tajammal in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.93, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Rutaba Tajammal's median patient age at 73, with 66% women.

In 2024, Rutaba Tajammal wrote 3,274 Medicare Part D claims for 435 patients. 90% of them were for generic drugs. CMS names the drug for 2,694 of them, across 72 drugs with 11 or more claims each, at $130,700 in total drug cost. In 2023, CMS named 349 claims across 16 drugs.

Rutaba Tajammal accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Rutaba Tajammal, published from 2018 to 2022. 2018 was the busiest year, with 2. Rutaba Tajammal has published most often in Cureus. Rutaba Tajammal's most frequent co-authors are Sultan Mahmood, MD, Taseen Ahmed Syed, MD and Nazir Ahmad, MBBS, MD.

CMS Open Payments shows 13 general payments to Rutaba Tajammal from 5 drug and device companies from 2022 to 2023. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $102.